Last reviewed · How we verify
Amikacin Injection
Amikacin is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death.
Amikacin is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death. Used for Serious gram-negative bacterial infections, Pseudomonas aeruginosa infections, Hospital-acquired infections caused by resistant gram-negative organisms.
At a glance
| Generic name | Amikacin Injection |
|---|---|
| Also known as | Amikacin, Amikin |
| Sponsor | Murdoch Childrens Research Institute |
| Drug class | Aminoglycoside antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amikacin irreversibly binds to the 30S ribosomal subunit of susceptible bacteria, disrupting accurate mRNA translation and causing misreading of the genetic code. This results in production of non-functional proteins and ultimately bactericidal activity against aerobic gram-negative bacteria and some gram-positive organisms. It is particularly effective against resistant gram-negative pathogens including Pseudomonas aeruginosa and Acinetobacter species.
Approved indications
- Serious gram-negative bacterial infections
- Pseudomonas aeruginosa infections
- Hospital-acquired infections caused by resistant gram-negative organisms
- Mycobacterial infections (including atypical mycobacteria)
Common side effects
- Nephrotoxicity (acute kidney injury)
- Ototoxicity (hearing loss, tinnitus, vertigo)
- Neuromuscular blockade
- Injection site reactions
- Rash
Key clinical trials
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection (PHASE1)
- Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections (PHASE3)
- Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection (NA)
- the Incidence of Necrotizing Enterocolitis in Preterm With Respiratory Distress Syndrome Undergoing Caffeine Therapy (EARLY_PHASE1)
- Endophthalmitis Post Intravitreal Injections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amikacin Injection CI brief — competitive landscape report
- Amikacin Injection updates RSS · CI watch RSS
- Murdoch Childrens Research Institute portfolio CI